Entrada (TRDA): Price-to-Revenue Ratio

Brandmark of Entrada Therapeutics Inc. (TRDA)

Unique patent protection for its intracellular delivery platform shields Entrada Therapeutics (TRDA) from price competition. The price-to-sales multiple filters out market noise, while the 50.80 mark reflects the current valuation. The financial success of Entrada Therapeutics (TRDA) relies on future sales of Duchenne muscular dystrophy treatments. Its status as a scientific pioneer in brain and muscle therapy strengthens the confidence of the global community.

TRDA Entrada Therapeutics P/S Multiple (05/21/2023 - 11/13/2026)

Analytical breakdowns for Entrada (TRDA)

- current quotes and average value forecast:
Market Price entradatx.com|TRDA - Price Target Chart
- stock exchange capitalization data:
Market Value Entrada|TRDA - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Entrada Therapeutics|TRDA - Book Capitalization|Market Value to Equity Ratio entradatx.com|TRDA - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Entrada Therapeutics|TRDA - Long-Term Debt to Capital|Current Liabilities to Capital Entrada Therapeutics, Inc|TRDA - Company Debts|Debt to Book Value Ratio Entrada|TRDA - Company Long-Term Liabilities|Amount of Current Liabilities Entrada Therapeutics|Intermediate Coverage Ratio entradatx.com
- earnings and multiples data:
TRDA - Net Profit|Projected Future Earnings Entrada Therapeutics|TRDA - P/E Multiple|Price to Future Earnings Ratio Entrada Therapeutics Inc.|TRDA - PEG Multiple|EV/EBITDA Multiple Entrada|TRDA - Operating profit before deduction of amortization|Earnings per share for the trailing year Entrada Therapeutics|TRDA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months entradatx.com|TRDA - Earnings growth in current year|Expected earnings per share trend next year Entrada Therapeutics
- issuer revenue and sales details:
TRDA - Revenue and Sales Volume|Company Expected Sales Volume entradatx.com|TRDA - Price-to-Revenue Ratio|Forward Price to Sales Entrada
Fundamental company analysis:entradatx.com (TRDA)
Mass-produced product of Entrada Therapeutics, Inc.

The P/S ratio determines the market value of a business relative to its annual sales, allowing an investor to identify a fair valuation range and the risks of capital stagnation. By analyzing the calculated price-to-sales ratio, one can assess the capitalization efficiency of Entrada Therapeutics (TRDA), whose value is currently based on the potential of neuromuscular disease therapies and the costs of maintaining high-tech laboratories.

Who Entrada Therapeutics competes with

JAZZ - Price to Sales|Price-to-Revenue Ratio Cytokinetics, Incorporated CYTK|PTC Therapeutics Inc - Price-to-Revenue Ratio|SRRK - Price-to-Revenue Ratio|Price to Sales Centessa Corp|DYN: P/S Multiple|Price-to-Revenue Multiple edgewisetx.com EWTX|Market Cap to Revenue RAPP|Price to Sales Alumis Inc ALMS|P/S Multiple ZVRA|CTNM - Price to Sales|Price-to-Revenue Ratio Larimar Therapeutics LRMR|CAPR: Market Cap to Revenue Ratio|PTHS: Market Cap to Revenue|MediciNova, Inc. - Market Cap to Sales Volume|Serina (SER) - Price-to-Revenue Ratio|BioXcel Therapeutics Corp - Market Capitalization-to-Revenue Ratio|PMN (ProMIS Neurosciences Inc.) - P/S Multiple|P/S Multiple Apimeds|P/S Multiple AEON|nlspharma.com - Market Cap to Revenue Ratio|P/S Multiple BNOX (Bionomics)|P/S Multiple fsdpharma.com HUGE|RETA: Market Cap to Revenue